CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO)

Q: What does CUSIP 71902K105 represent in this 13F holders report?

CUSIP 71902K105 is the security identifier for CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share in Q2 2025?

1 institutional investor reported CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 71902K105

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class: Equity / Common Stock, $0.0001 par value per share
Total 13F shares: 400
Total 13F value: $24
Share change: +400
SEC-reported price per share: $0.06
Number of holders: 1
Value change: +$24
Number of buys: 1
Shares outstanding: 5,169,697

Security key

71902K105

Report period

Q2 2025

Institutions

Top holders

CERO full security history Ownership snapshot Previous quarter: Q1 2025 CERO THERAPEUTICS HOLDINGS, INC. SEC filings CERO THERAPEUTICS HOLDINGS, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 71902K105

Previous quarter: Q1 2025

Recent filing periods:

Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023

Ownership snapshot

Top reported holders of CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Brian G. Atwood

Disclosed value leader

Stuart M. Sloan

Comparable rows

14/15

Latest evidence

30 Jun 2025

13D/G 13F 3/4/5 Lead comparable stake: 9.9% 1 rows are not safely comparable across share classes. 13D/G row: Brian G. Atwood Showing 1-6 of 15 holder rows.

Quick read

Brian G. Atwood leads the comparable SEC ownership view at 9.9%.

14 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Brian G. Atwood's linked filing trail.

Comparable ownership Top 5

Brian G. Atwood 9.9%

ARMISTICE CAPITAL, LLC 5%

YK Bioventures Opportunities GP I... 0.33%

Avantax Planning Partners, Inc. 1.3%

UBS Group AG 0.73%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Brian G. Atwood	13D/G 13D/G	9.9%	$20,472 511,800 shares	+$12,376	31 Mar 2025
ARMISTICE CAPITAL, LLC	13D/G 13F Company 13D/G 13F	5%	$552,046 63,308 shares	$0	30 Jun 2025
YK Bioventures Opportunities GP I, LLC	3/4/5 13D/G 10%+ Owner 3/4/5 13D/G	0.33% from 13D/G	$780,310 13,005,169 shares	—	11 Dec 2024
Avantax Planning Partners, Inc.	13F Company 13F	1.3%	$54,254 74,321 shares	—	31 Mar 2025
UBS Group AG	13F Company 13F	0.73%	$31,162 42,687 shares	—	31 Mar 2025
ARCH Venture Management, LLC	13F Company 13F	0.38%	$16,134 22,102 shares	—	31 Mar 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Archived quarter

Historical 13F summary for Q2 2025

This older quarter remains available as an indexed ownership summary. Detailed holder rows are no longer kept in the hot table for this period.

CERO full security history Previous quarter: Q1 2025